Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma

In conclusion, Pembrolizumab with Vorinostat was tolerable and produced responses in relapsed/refractory B-cell NHL, with particularly notable efficacy in PMBL.PMID:37470137 | DOI:10.3324/haematol.2023.283002

Source: Haematologica - July 20, 2023 Category: Hematology Authors: James Godfrey Matthew Mei Lu Chen Joo Y Song Victoria Bedell Elizabeth Budde Saro Armenian Sandrine Puverel Liana Nikolaenko Robert Chen Shari Daniels Neena Kennedy Lacolle Peters Steven T Rosen Stephen J Forman Leslie L Popplewell Larry W Kwak Alex F Her Source Type: research